Please join us for the 5th Annual Canadian Multidisciplinary Hepatobiliary Cancer Conference taking place on October 1st & 2nd, 2026 at the Omni King Edward Hotel in Toronto, Ontario, Canada.
We are excited to announce; this year we will be organizing CMHCC in conjunction with the inaugural Canadian GI Cancer Conference (CGCC).
CLICK HERE TO ACCESS THE RECORDED SESSIONS
CMHCC will showcase international and national experts and create an opportunity for colleagues to come together and discuss latest research in HCC and Biliary cancer.
This informative conference provides a unique opportunity for attendees to participate in presentations from international experts in the field of Multidisciplinary Hepatobiliary Cancer. The scope of this meeting will highlight both recent research findings elucidating the pathophysiology of these diverse diseases, as well as changes in therapeutic advances that have had a large impact in the management of our patients.
We hope you will attend this educational event and much needed networking opportunity!
See you in Toronto, October 2026!
CMHCC Chairs
Laura Dawson, MD, FRCPC, FASTRO, University of Toronto
Rachel Goodwin, MSc, MD, FRCPC, University of Ottawa
Brandon Meyers, MSc, MD, FRCPC, McMaster University
Vincent Tam, MD, FRCPC, University of Calgary
Target Audience
Medical Oncologists, Radiation Oncologists, Interventional Radiologists, Surgical Oncologists Hepatologists, Internists, as well as Residents, Nurse Practitioners and Pharmacists, with an interest in HCC and/or biliary cancer.
Learning Objectives:
Early-Stage Disease
- Establish principles of non-surgical techniques for curative intent management
- Review the evidence of liver transplant, and aspects of patient selection
- Examine the data on surgical management of early stage HCC
Intermediate Stage Disease
- Review the evidence available in defining what is TACE refractory disease and
what other options are - Examine the data on systemic therapy in intermediate stage HCC
- Evaluate both the strengths and limitations of the BCLC staging system
Advanced Stage Disease
- Review the existing data on current systemic therapy for advanced/metastatic biliary tract cancer with a focus on biomarker development and future systemic therapy options.
- Review the existing data on current systemic therapy for advanced HCC as well as future systemic therapy options.
- Facilitate open discussion and cross disciplinary knowledge translation using case-based discussion for biliary cancer and hepatocellular carcinoma.